Published in Hospital and Nursing Home Week, September 8th, 2005
In preclinical models, NGX267 has shown properties suggesting potential as a therapy for symptomatic improvement and disease modification in Alzheimer disease.
Neil Kurtz, MD, chief executive officer at TorreyPines Therapeutics, said, "NGX267 is the first of several small molecule compounds we are developing to treat Alzheimer's disease."
The phase 1 clinical trial will be conducted at one center in Arizona and will enroll approximately 55 healthy volunteers. The single dose trial will focus on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week